Carsten Hofmann

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

21h-index2.0kcitations68works4.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(27), Dementia and Cognitive Impairment Research(13), Health Systems, Economic Evaluations, Quality of Life(10), Statistical Methods in Clinical Trials(10), Microbial Natural Products and Biosynthesis(8)

Publications68 total

Latest results from the dose‐expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer’s disease
Alzheimer s & Dementia·2025Open Access
TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer’s disease
Alzheimer s & Dementia·2025Open Access
Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s disease
Alzheimer s & Dementia·2025· 1 citedOpen Access
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
The Lancet Neurology·2025· 27 cited
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)
Journal of Alzheimer s Disease·2024· 2 citedOpen Access
Safety of higher doses of gantenerumab in the open‐label extension of the DIAN–TU‐001 trial
Alzheimer s & Dementia·2024Open Access
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer’s disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial
2024· 4 citedOpen Access
Long-Term Safety of Gantenerumab in Participants with Alzheimer’s Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)
Journal of Alzheimer s Disease·2024· 5 citedOpen Access
At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact
The Journal of Prevention of Alzheimer s Disease·2024· 3 citedOpen Access
Amyloid Reduction and Dementia Progression in Dominantly Inherited Alzheimer's Diseaseafter Long-Term Gantenerumab Treatment: Results from the Dian-Tu Trial
SSRN Electronic Journal·2024· 4 citedOpen Access
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans
mAbs·2023· 135 citedOpen Access
Enabling Subcutaneous Dosing of Gantenerumab in Alzheimer’s Disease (S14.006)
Neurology·2023
Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model)
Alzheimer s & Dementia·2022· 9 citedOpen Access
Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer’s disease and the effects of anti‐amyloid treatment
Alzheimer s & Dementia·2022
Baseline participant characteristics of GRADUATION: a study to evaluate once‐weekly subcutaneous administration of gantenerumab
Alzheimer s & Dementia·2022· 1 cited
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates
CPT Pharmacometrics & Systems Pharmacology·2022· 19 citedOpen Access
Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Annals of Neurology·2022· 34 citedOpen Access
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies
Journal of Pharmacokinetics and Pharmacodynamics·2022· 6 citedOpen Access
Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease
Clinical Pharmacology & Therapeutics·2022· 15 citedOpen Access
In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
Alzheimer s & Dementia Translational Research & Clinical Interventions·2022· 17 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Paul Delmar(17), Gregory Klein(16), Rachelle S. Doody(14), Paulo Fontoura(12), Monika Baudler(11), Geoffrey A. Kerchner(10), Andreas Bechthold(9), Meret Martin‐Facklam(8), Danielle Abi‐Saab(7), Mirjana Andjelković(6), Randall J. Bateman(6), Jakub Wojtowicz(6), Tobias Bittner(6), Bruno Dubois(5), Nicola Voyle(5), Guoqiao Wang(5), Steffen J. Glaser(5), Serge Gauthier(5), Jason Hassenstab(5), Mario Masellis(5)